Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (14091)	7/11/2000 10:10:57 PM
From: Bluegreen	Respond to of 17367

Exactly, George! That is why I say Baxter and Xoma need to take any patent application like this VERY SERIOUS.

To: aknahow who wrote (14091)	7/12/2000 5:53:35 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, I was passing by your clubhouse and heard you screaming to your members something about analysts and anti-cd11a. One analyst was referring to "experts." Why couldn't the volume increase be due to possible roll out of cancer product or products into human studies?????>>>>>>>>>>>>>>``All the experts feel this is the most exciting compound in clinical trials for psoriasis,'' said Matthew Geller, an analyst with CIBC World Markets, who rates the stock a ``buy.'' ``They could have a real blockbuster with this drug.'' The company also has two other antibody products for treating cancer, which could move into human studies over the next 12 to 18 months, Augustine said in his report.<<<<<<